Le Lézard
Classified in: Health, Science and technology
Subject: PER

Longtime Mayo Clinic Neurologist Dr. Richard J. Caselli Joins SPARK Neuro as Medical Director


LOS ANGELES, April 16, 2024 /PRNewswire/ -- SPARK Neuro, a leader in brain health diagnostics, announces the appointment of Dr. Richard J. Caselli as its Medical Director. With a 35-year career at the Mayo Clinic, Dr. Caselli brings extensive expertise and leadership in neurology and cognitive aging to SPARK Neuro. His appointment underscores the company's commitment to advancing the medical field.

During his tenure at Mayo Clinic, Dr. Caselli and his team collaborated with SPARK Neuro on several research initiatives funded by the National Institutes of Health. These collaborations have led to groundbreaking methods in brain health measurement, including SPARK Neuro's achievement of FDA clearance. Their AI-enabled EEG brain scan technology and dementia assessment service offer more accurate and efficient dementia diagnosis, which is currently underdiagnosed by 40%.

Spencer Gerrol, CEO of SPARK Neuro, stated, "Dr. Caselli's vast experience and achievements make him a tremendous asset to our mission, including enhancing solutions for patients with Alzheimer's and other forms of dementia."

Dr. Caselli's distinguished career includes serving as Chair of the Department of Neurology, Medical Director of Patient Experience, and Director of Research at the Mayo Clinic. Under his leadership, the Mayo Clinic achieved top scores for patient satisfaction.

Dr. Caselli's role as the Clinical Core Director of the Arizona Alzheimer's Disease Center led to significant contributions to the field. His scholarly work includes over 300 original scientific publications in top medical journals, establishing Dr. Caselli as a leading authority in neurology.

Reflecting on his new position, Dr. Caselli said, "Joining SPARK Neuro offers a unique opportunity to advance neurodiagnostics and brain health monitoring, building on our shared history of collaboration."

With Dr. Caselli's leadership, SPARK Neuro will continue to make brain health assessment more universal and accessible in the real world.

About SPARK Neuro:
SPARK Neuro's mission is to make brain health assessments a standard part of care. Targeting the 40% of dementia cases that are undiagnosed, SPARK provides a comprehensive assessment service for healthcare payers and providers, propelled by its AI-enabled and FDA-cleared EEG brain scan. SPARK Neuro has a history of collaborating with prestigious institutions like the Mayo Clinic and Johns Hopkins Medicine and has earned funding from the Department of Defense and the National Institutes of Health. SPARK Neuro's flagship innovation delivers an objective, non-invasive, and scalable approach to brain health assessment. For more information, visit https://sparkneuro.com/.

Media Contact:
Alexandra Pardue
Communications Manager 
SPARK Neuro
[email protected]

SOURCE SPARK Neuro


These press releases may also interest you

at 16:20
Acadia Pharmaceuticals Inc. today announced that it has awarded 10 academic scholarships to eligible recipients of the first Rett Sibling Scholarship. The Rett Sibling Scholarship program, sponsored by Acadia, was established in 2023 to recognize...

at 16:15
BD (Becton, Dickinson and Company) , a leading global medical technology company, today announced that it will present at the Bank of America Securities Health Care Conference 2024 on Tuesday, May 14, 2024 at 11:00 am Eastern Time. The live webcast...

at 16:11
Xavier University of Louisiana (Xavier), a leading undergraduate institution in preparing Black students to successfully complete medical school, has announced continued progress with Ochsner Health (Ochsner), the Gulf South's leading academic...

at 16:10
CareDx, Inc. ? The Transplant Companytm focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers ? today announced it will report financial...

at 16:10
biote Corp. ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has entered into a definitive settlement agreement...

at 16:05
MorphoSys AG reports results for the first quarter of 2024. "The proposed acquisition by Novartis is advancing steadily, and we continue to anticipate its closure in the first half of 2024. The acceptance period for the acquisition is currently...



News published on and distributed by: